What's the recommended testing frequency for lurbinectedin's side effects?

Lurbinectedin (Zepzelca) doesn’t have a single universal “side‑effect testing frequency” that covers every patient, because monitoring depends on which adverse effects a person is getting risk for (especially blood count issues and liver/kidney abnormalities) and their overall status.

That said, standard clinical practice and the product’s monitoring guidance generally involve:

1) Blood counts (myelosuppression: neutropenia, anemia, thrombocytopenia)

• CBC (complete blood count) is typically checked before each dose.
• If there are prior low counts or symptoms, clinicians may also do more frequent CBC monitoring during treatment cycles (commonly within days of the dose or as needed), but the baseline expectation is at least every cycle / prior to each administration.

2) Liver tests (hepatotoxicity: ↑ AST/ALT, bilirubin)

• LFTs (AST, ALT, alkaline phosphatase, total bilirubin) are typically checked before each dose.
• As with CBC, if abnormalities are found, testing is usually more frequent until labs improve, and dosing may be delayed/reduced.

3) Renal function / electrolytes (less emphasized than CBC/LFTs but still monitored)

• Creatinine/eGFR is commonly checked periodically and often before each dose as part of routine chemistry panels.
• Additional electrolytes may be monitored depending on comorbidities and what else is going on clinically.

4) Symptom monitoring (not just labs)

Clinicians also monitor for:

• Infection signs/fever (especially with neutropenia)
• Bleeding/bruising (thrombocytopenia)
• Fatigue, shortness of breath
• Nausea/vomiting, diarrhea, mucositis These are assessed at each visit and sometimes more often between visits.

Quick practical answer

Most of the time: labs are monitored at least once per dosing cycle—before every dose, with CBC and liver function tests being the key ones. If abnormalities occur, the monitoring frequency increases (often weekly or more often depending on severity and treatment delays).

If you tell me:

1. the dose schedule (every 3 weeks vs weekly, etc.),
2. whether it’s small cell lung cancer and what line of therapy, and
3. whether you’re asking about clinical trial protocol vs prescribing info vs your oncologist’s plan,
   I can give a more specific “how often” schedule.